LOGIN  |  REGISTER
Cue Biopharma
Recursion

McKesson Raises Quarterly Dividend by 15% to $0.62 Per Share

July 24, 2023 | Last Trade: US$673.05 0.77 -0.11

IRVING, Texas / Jul 24, 2023 / Business Wire / The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023.

“The dividend increase reflects confidence in our strategy and ability to generate sustained strong cash flows,” said Brian Tyler, chief executive officer. “We continue to remain disciplined in our approach to capital deployment and focused on driving sustainable growth while creating value for our shareholders.”

McKesson has increased its dividend for seven consecutive years.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page